Media coverage about Spark Therapeutics (NASDAQ:ONCE) has trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spark Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.0738267575666 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
- Spark Therapeutics, Inc. (NASDAQ:ONCE) Sees Significantly Higher Trading Volume – First News 24 (firstnewspaper24.com)
- Spark Therapeutics, Inc. (ONCE) Research Coverage Started at Barclays PLC (americanbankingnews.com)
- Barclays Starts Coverage on Spark Therapeutics, Inc. (ONCE) With An Initial Rating Of “Overweight” (highlightpress.com)
- Spark Therapeutics Announces Publication of Study Confirming Novel Test’s Validity, Reliability and Ability to Detect Change in Functional Vision (finance.yahoo.com)
- Spark Therapeutics Is Ready to Catch Fire (finance.yahoo.com)
A number of research firms recently issued reports on ONCE. BMO Capital Markets reaffirmed an “outperform” rating and issued a $89.00 target price (up previously from $69.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Chardan Capital raised Spark Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $60.00 to $100.00 in a research report on Tuesday, August 8th. Cowen and Company reaffirmed an “outperform” rating and issued a $95.00 target price (up previously from $75.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Zacks Investment Research downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, BidaskClub raised Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $83.77.
Shares of Spark Therapeutics (ONCE) opened at 82.22 on Monday. The company’s market capitalization is $2.57 billion. The company has a 50 day moving average price of $77.32 and a 200 day moving average price of $62.21. Spark Therapeutics has a 52 week low of $35.07 and a 52 week high of $86.86.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter in the prior year, the firm posted ($1.04) earnings per share. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. On average, equities research analysts expect that Spark Therapeutics will post ($7.69) earnings per share for the current year.
In other Spark Therapeutics news, CFO Stephen W. Webster sold 7,663 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $60.00, for a total value of $459,780.00. Following the completion of the transaction, the chief financial officer now directly owns 10,163 shares of the company’s stock, valued at approximately $609,780. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Katherine A. High sold 10,000 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the transaction, the insider now directly owns 220,000 shares of the company’s stock, valued at $13,200,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 371,160 shares of company stock valued at $26,468,351. Insiders own 7.30% of the company’s stock.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Spark Therapeutics (ONCE) Share Price” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://sportsperspectives.com/2017/09/11/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-spark-therapeutics-once-share-price.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.